FDA批准诺瑞匹坦预防化疗引起的恶心和呕吐

Formulary Pub Date : 2016-06-10 DOI:10.1211/pj.2015.20069288
Daniel S. Raccuia, Pharmd Candidate, L. Holle, Pharmd, Bcop, Fhopa
{"title":"FDA批准诺瑞匹坦预防化疗引起的恶心和呕吐","authors":"Daniel S. Raccuia, Pharmd Candidate, L. Holle, Pharmd, Bcop, Fhopa","doi":"10.1211/pj.2015.20069288","DOIUrl":null,"url":null,"abstract":"Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.","PeriodicalId":12354,"journal":{"name":"Formulary","volume":"71 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2016-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"FDA approves rolapitant to prevent chemotherapy-induced nausea and vomiting\",\"authors\":\"Daniel S. Raccuia, Pharmd Candidate, L. Holle, Pharmd, Bcop, Fhopa\",\"doi\":\"10.1211/pj.2015.20069288\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.\",\"PeriodicalId\":12354,\"journal\":{\"name\":\"Formulary\",\"volume\":\"71 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Formulary\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1211/pj.2015.20069288\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Formulary","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1211/pj.2015.20069288","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

罗拉匹坦是一种新型的NK1受体拮抗剂,在单次180毫克剂量后5天内保持>90%的受体结合。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
FDA approves rolapitant to prevent chemotherapy-induced nausea and vomiting
Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Formulary
Formulary 医学-药学
自引率
0.00%
发文量
14
审稿时长
>12 weeks
期刊最新文献
FDA approves rolapitant to prevent chemotherapy-induced nausea and vomiting You get what you need FDA expands Zytiga's use for late-stage prostate cancer Eyes to see, ears to hear This is pharmacy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1